StockData
NeoGenomics Inc logo

NeoGenomics Inc (NEO) company profile

NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/3023% below fair value
$15.25−0.16 (-1.04%)

Close on Nov 17, 2026Market cap $1.97BP/E –Yield –

About NeoGenomics

Services-Testing Laboratories, SIC 8734

NeoGenomics, Inc. provides oncology diagnostic testing, technical laboratory services, and professional test interpretations by specialized physicians and molecular experts. The company operates under a single reportable segment encompassing services such as molecular and next-generation sequencing testing, cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, morphologic analysis, and molecular residual disease testing. Additionally, it offers clinical trial and research support services, validation laboratory services, and oncology data solutions. Its customer base includes community-based oncology and pathology practices, hospital laboratories, reference laboratories, academic centers, and pharmaceutical companies.

The company operates a network of testing laboratories across the United States—specifically in Arizona, California, Florida, Georgia, Illinois, New Jersey, North Carolina, Tennessee, and Texas—as well as a sample-processing laboratory in Cambridge, United Kingdom. As of late 2025, the organization employed approximately 2,500 full-time equivalent personnel, including contracted pathologists and around 135 physicians and doctoral specialists. The provided text does not state the company's headquarters location.

Summary of the business section of NeoGenomics's latest annual report, written by StockData.

Company profile

Company

Legal name
NeoGenomics Inc
Founded
2002
Headquarters
Fort Myers, FL
Address
9490 Neogenomics Way 33912
Phone
(239) 768-0600
Employees
2,500, Dec 31, 2025
Industry
Services-Testing Laboratories
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Diego, California

Stock & identifiers

Ticker
NEO
Exchange
Nasdaq
IPO date
Mar 16, 2004
Shares outstanding
129M, Oct 23, 2026
Public float
$680.20M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1077183
CUSIP
64049M209
ISIN
US64049M2098
FIGI
BBG000BKH263
Share class FIGI
BBG001S9DSY4
LEI
254900KXWYZIKXNFT521
EIN
74-2897368

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Anthony P. ZookChief Executive Officer, Director152,011
Warren StonePres & Chief Operating Officer191,729
Alicia C. OlivoEVP, GC & Business Development90,875
Greg D. AunanChief Accounting Officer5,153
Abhishek JainChief Financial Officer–
Jeffrey Scott ShermanChief Financial Officer220,009
Melody HarrisChf Ops Off, Pres, Informatics109,755
Christopher M. SmithChief Executive Officer641,585
Carolyn S. StarrettDirector–
Lynn A. TetraultDirector93,115
David Brian PerezDirector66,967
Stephen M. KanovskyDirector75,421
Felicia WilliamsDirector30,237
John P. KennyDirector5,893
Michael Aaron KellyDirector72,086
Neil GunnDirector51,177
Marjorie C. GreenDirector22,964
Elizabeth FloegelDirector23,590
Alison L. HannahDirector131,023

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Christopher Smith
$4.05M-$10.93M$3.81M$22$125
FY2025
Tony Zook
$9.14M$11.90M$3.81M$22$125
FY2024$11.34M$10.32M$2.81M$56$118
FY2023$11.67M$16.41M$3.41M$55$119
FY2022
Christopher Smith
$14.80M$11.33M$2.69M$32$114
FY2022
Lynn Tetrault
$2.07M$1.95M$2.69M$32$114

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Tony Zook
Director and Chief Executive Officer
$601.54K–$4.00M$4.00M$513.40K$13.92K$9.13M–
Christopher Smith
Former Director and Former Chief Executive Officer
$310.96K–$3.35M–$155.75K$229.22K$4.05M-64%
Jeffrey Sherman
Chief Financial Officer
$603.73K$50.00K$2.25M$1.50M$264.00K$14.00K$4.68M+34%
Warren Stone
Chief Commercial Officer
$630.07K$400.00K$2.25M$1.50M$275.00K$14.00K$5.07M+59%
Alicia Olivo
Executive Vice President, General Counsel and Business Development
$522.50K$75.00K$1.50M$749.85K$196.00K$6.65K$3.05M+36%
Gary Passman
Chief Culture Officer
$447.96K$75.00K$1.12M$624.88K$164.00K$6.36K$2.44M–
Melody Harris
Former Chief Operations Officer and Former President, Oncology Data Solutions
$269.23K$152.33K$1.67M$912.85K–$691.39K$3.69M+28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 2,500 full-time equivalent employees including contracted pathologists.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 24, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 27, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 13, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 13, 2019Late filingNotification of late filing
Mar 5, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 10, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 9, 2017Late filingNotification of late filing
Dec 31, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 13, 2015Merger voteDefinitive merger proxy statement
Nov 12, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 10, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 15, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 7, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 11, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 5, 2012ListingRegistration of securities on an exchange (Form 8-A)
Nov 16, 2009Late filingNotification of late filing
Mar 31, 2009Late filingNotification of late filing
Mar 31, 2008Late filingNotification of late filing
Nov 14, 2007Late filingNotification of late filing
Aug 15, 2007Late filingNotification of late filing
Nov 14, 2006Late filingNotification of late filing
Apr 3, 2006Late filingNotification of late filing
Mar 30, 2005Late filingNotification of late filing
May 16, 2003Late filingNotification of late filing
Mar 31, 2003Late filingNotification of late filing
Nov 15, 2002Late filingNotification of late filing
May 16, 2002Late filingNotification of late filing
Apr 1, 2002Late filingNotification of late filing
Feb 5, 2002Name changeName changed from AMERICAN COMMUNICATIONS ENTERPRISES INC to NeoGenomics Inc
Nov 14, 2001Late filingNotification of late filing

See a number that looks wrong?